Identification of Potential Markers Related to Neoadjuvant Chemotherapy Sensitivity of Breast Cancer by SELDI-TOF MS

Abstract

Neoadjuvant chemotherapy (NACT) is known to be beneficial for patients with locally advanced breast cancer. However, there is still no unified standard on the evaluation of NACT. To identify the potential markers related to NACT sensitivity of breast cancer, in the present study, we examined the protein spectrum of breast cancer tissues before and after NACT using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Totally, 87 protein samples were extracted from tissues of breast cancer, with 30 from patients before NACT, 30 from patients after NACT, and 27 from patients without any treatment. To eliminate confounding factors a couple of tissue samples from the same patient were mixed. SELDI-TOF MS analysis demonstrated that the intensities of eight different protein peaks, i.e., 26,055.46, 17,898.94, 8,949.50, 11,652.02, 11,053.48, 38,546.56, 5,825.89, and 22,250.63 Da, were higher in samples after NACT than those before NACT. Although further experiments are needed to prove the reliability of the proteins identified in this study, our results will help the establishment of protein model based on drug resistance-related protein peaks to screen whether a patient is suitable for adopting NACT and to improve cancer treatment.

Imaging mass spectrometry to discriminate breast from pancreatic cancer metastasis in formalin‐fixed paraffin‐embedded tissues

“…Mass spectrometric-based proteomic approach has been successfully applied to identify tumor-associated proteins as biomarkers in various cancers [11][12][13]. Several studies using MALDI technology have identified potential diagnostic, prognostic, and therapeutic markers [7,[14][15][16][17][18][19][20][21][22][23]. Furthermore, MALDI IMS is an ideal method to show the heterogeneity of the tissue or of tumor samples [7,23].…”

Tissue biomarkers of breast cancer and their association with conventional pathologic features

“…Included among proteins previously identified from breast tumour tissue lysates are albumin fragments (Gast et al , 2009) and complement C3a (Zhang et al , 2012), both presumably derived from the circulation. Tissue proteomic profiling using SELDI-TOF MS has also yielded peak clusters that can contribute to the classification of breast tumours into molecular subtypes (Brozkova et al , 2008; Goncalves et al , 2008) that resemble the luminal A and B, basal, and HER2-like subtypes defined by gene expression analysis (Reis-Filho and Pusztai, 2011).…”

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy

“…They detected only a single chemotherapy-inducible SELDI-MS peak [mass/charge ratio (m/z), 2790] that was induced by paclitaxel and, to a lesser extent, by FAC chemotherapy. Recently, the intensities of eight different protein peaks were demonstrated to be higher in breast cancer tissue extracts after neoadjuvant chemotherapy than those before neoadjuvant chemotherapy (24). Although further experiments are needed to prove the reliability of these eight proteins, these results will help in the establishment of protein models based on drug resistance-related protein peaks to screen whether a patient is suitable for adopting neoadjuvant chemotherapy and to improve cancer treatment.…”